Martins J, Vaz AF, Grion RC, et al. - The effects of different therapeutic options in prevention of the evolution of vaginal stenosis after pelvic radiotherapy in women with cervical cancer were investigated in this open-label randomized clinical trial. Researchers herein assessed a total of 195 women, stage I-IIIB, aged 18–75 years, using topical estrogen (66), topical testosterone (34), water-based intimate lubricant gel (66), and vaginal dilators (29). Per analysis, all treatment groups showed a reduction in vaginal volume, with no significant difference between them. However, there was a lower frequency and severity of vaginal stenosis assessed by the Common Terminology Criteria for Adverse Events scale after 1 year of treatment among women who used vaginal dilators.